This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
US pharma major AbbVie (NYSE: ABBV) presented new data on Thursday on patients with genotype 1 chronic hepatitis C virus (HCV) infection who took Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir)–Holkira or Viekira Pak.
Treated with or without ribavirin (RBV), they achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).
The data comes from a post-hoc analysis of five completed Phase III clinical trials and was presented at The International Liver Congress 2016 in Barcelona. It was found that no matter whether certain RAVs, called NS5A, were present, all 148 of patients with genotype 1b chronic HCV infection, who received Viekirax and Exviera without RBV for 12 weeks, achieved SVR48.
Results also showed 97% of patients with genotype 1a (GT1a) chronic HCV infection with or without baseline NS5A RAVs achieved SVR48 when receiving the combination with RBV.